Simufilam is a novel oral
drug candidate in Phase 3 clinical trials for
Alzheimer's disease (AD)
dementia. This small molecule binds an altered form of
filamin A (FLNA) that occurs in AD. This
drug action disrupts FLNA's aberrant linkage to the α7
nicotinic acetylcholine receptor (α7nAChR), thereby blocking soluble
amyloid beta1-42 (Aβ42)'s signaling via α7nAChR that hyperphosphorylates tau. Here, we aimed to clarify
simufilam's mechanism. We now show that
simufilam reduced Aβ42 binding to α7nAChR with a 10-picomolar IC50 using time-resolved fluorescence resonance energy transfer (TR-FRET), a robust technology to detect highly sensitive molecular interactions. We also show that FLNA links to multiple inflammatory receptors in addition to
Toll-like receptor 4 (TLR4) in postmortem human AD brains and in AD transgenic mice: TLR2,
C-X-C chemokine receptor type 4 (CXCR4),
C-C chemokine receptor type 5 (CCR5), and T-cell co-receptor cluster of differentiation 4 (CD4). These aberrant FLNA linkages, which can be induced in a healthy control brain by Aβ42 incubation, were disrupted by
simufilam.
Simufilam reduced inflammatory
cytokine release from Aβ42-stimulated human astrocytes. In the AD transgenic mice, CCR5-G
protein coupling was elevated, indicating persistent activation. Oral
simufilam reduced both the FLNA-CCR5 linkage and the CCR5-G
protein coupling in these mice, while restoring CCR5's responsivity to
C-C chemokine ligand 3 (CCL3). By disrupting aberrant FLNA-receptor interactions critical to AD pathogenic pathways,
simufilam may promote brain health.